Advances in crystallography and protein spectroscopy have accelerated the discovery of active sites or "binding pockets" within specific biologic targets. These advances, combined with structure-based drug design, have allowed biotechs to develop highly specific small-molecule inhibitors with far less guesswork, and in turn far smaller budgets.
Blood cancers depend on the dysregulation of key cellular pathways and processes. Improved understanding of those processes and pathways has resulted in an unprecedented number of drugs specifically designed to target them. At the recently concluded American Society of Clinical Oncology (OTC:ASCO) 2013 meeting, investigators presented dozens of studies concerning 11 new drugs developed to combat B-cell malignancies. All 11 were designed to specifically target one of five different proteins involved in...
Only subscribers can access this article, which is part of the PRO research library covering 3,602 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: